

Hong-Hu Zhu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8302767/publications.pdf>

Version: 2024-02-01

71
papers

1,800
citations

361413

20
h-index

302126

39
g-index

77
all docs

77
docs citations

77
times ranked

1923
citing authors

#	ARTICLE	IF	CITATIONS
1	The first report of complete remission following treatment with venetoclax plus prednisone in elderly patients with Philadelphia chromosome-negative acute lymphoblastic leukemia. <i>Annals of Hematology</i> , 2022, 101, 1141-1144.	1.8	5
2	Venetoclax-ponatinib for T315I/compound-mutated Ph+ acute lymphoblastic leukemia. <i>Blood Cancer Journal</i> , 2022, 12, 20.	6.2	14
3	Venetoclax for arsenic-resistant acute promyelocytic leukaemia. <i>British Journal of Haematology</i> , 2022, 197, .	2.5	9
4	Venetoclax plus 3-azacitidine and cytarabine chemotherapy as first-line treatment for adults with acute myeloid leukaemia: a multicentre, single-arm, phase 2 trial. <i>Lancet Haematology</i> , 2022, 9, e415-e424.	4.6	38
5	A real-world study of infectious complications of venetoclax combined with decitabine or azacitidine in adult acute myeloid leukemia. <i>Supportive Care in Cancer</i> , 2022, 30, 7031-7038.	2.2	7
6	PRMT5-mediated RNF4 methylation promotes therapeutic resistance of APL cells to As2O3 by stabilizing oncoprotein PML-RAR α . <i>Cellular and Molecular Life Sciences</i> , 2022, 79, .	5.4	4
7	CDKN2A deletions are associated with poor outcomes in 101 adults with T-cell acute lymphoblastic leukemia. <i>American Journal of Hematology</i> , 2021, 96, 312-319.	4.1	15
8	Minimal residual disease level determined by flow cytometry provides reliable risk stratification in adults with T-cell acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2021, 193, 1096-1104.	2.5	8
9	Not BCL2 mutation but dominant mutation conversion contributed to acquired venetoclax resistance in acute myeloid leukemia. <i>Biomarker Research</i> , 2021, 9, 30.	6.8	11
10	A Pin1/PML/P53 axis activated by retinoic acid in NPM-1c acute myeloid leukemia. <i>Haematologica</i> , 2021, 106, 3090-3099.	3.5	11
11	Coagulation profile in newly diagnosed T-cell acute lymphoblastic leukemia. <i>Thrombosis Research</i> , 2021, 203, 69-71.	1.7	2
12	Case Report: The First Report of NUP214-ABL1 Fusion Gene in Acute Myeloid Leukemia Patient Detected by Next-Generation Sequencing. <i>Frontiers in Oncology</i> , 2021, 11, 706798.	2.8	2
13	Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants. <i>Blood Cancer Journal</i> , 2021, 11, 167.	6.2	11
14	Ruxolitinib Combined with Dexamethasone in Adult Patients with Secondary HLH: A Single-Centre Pilot Trial. <i>Blood</i> , 2021, 138, 198-198.	1.4	1
15	Early Death and Survival of Patients With Acute Promyelocytic Leukemia in ATRA Plus Arsenic Era: A Population-Based Study. <i>Frontiers in Oncology</i> , 2021, 11, 762653.	2.8	14
16	Ex Vivo Chemosensitivity Profiling of Acute Myeloid Leukemia and Its Correlation With Clinical Response and Outcome to Chemotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 793773.	2.8	4
17	Venetoclax and arsenic showed synergistic anti-leukemia activity in vitro and in vivo for acute myeloid leukemia with the NPM1 mutation. <i>American Journal of Hematology</i> , 2020, 95, E55-E57.	4.1	10
18	Biotransformation of arsenic trioxide by AS3MT favors eradication of acute promyelocytic leukemia: revealing the hidden facts. <i>Drug Metabolism Reviews</i> , 2020, 52, 425-437.	3.6	14

#	ARTICLE	IF	CITATIONS
19	The History of the Chemo-Free Model in the Treatment of Acute Promyelocytic Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 592996.	2.8	4
20	Balance between the toxicity and anticancer activity of arsenic trioxide in treatment of acute promyelocytic leukemia. <i>Toxicology and Applied Pharmacology</i> , 2020, 409, 115299.	2.8	29
21	Comparison of Early T-Cell Precursor and Non-ETP Subtypes Among 122 Chinese Adults With Acute Lymphoblastic Leukemia. <i>Frontiers in Oncology</i> , 2020, 10, 1423.	2.8	14
22	PML-RAR α interaction with TRIB3 impedes PPAR α /RXR function and triggers dyslipidemia in acute promyelocytic leukemia. <i>Theranostics</i> , 2020, 10, 10326-10340.	10.0	12
23	CAG regimen for refractory or relapsed adult T-cell acute lymphoblastic leukemia: A retrospective, multicenter, cohort study. <i>Cancer Medicine</i> , 2020, 9, 5327-5334.	2.8	6
24	Identification of a novel NUP98-RARA fusion transcript as the 14th variant of acute promyelocytic leukemia. <i>American Journal of Hematology</i> , 2020, 95, E184-E186.	4.1	10
25	An oral, chemotherapy-free regimen (dasatinib plus prednisone) as induction and consolidation for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia. <i>British Journal of Haematology</i> , 2020, 189, e231-e234.	2.5	5
26	Clinical Correlation of a Precision Medicine Test with Treatment Outcome in Acute Myeloid Leukemia Patients. <i>Blood</i> , 2020, 136, 1-2.	1.4	33
27	Bone marrow versus peripheral blood as a graft source for haploidentical donor transplantation in adults using post-transplant cyclophosphamide: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 133, 120-128.	4.4	35
28	hCINAP regulates the DNA-damage response and mediates the resistance of acute myelocytic leukemia cells to therapy. <i>Nature Communications</i> , 2019, 10, 3812.	12.8	31
29	The simpler, the better: oral arsenic for acute promyelocytic leukemia. <i>Blood</i> , 2019, 134, 597-605.	1.4	95
30	Identification of a point mutation PMLS214L-RAR α that alters PML body organization, dynamics and SUMOylation. <i>Biochemical and Biophysical Research Communications</i> , 2019, 511, 518-523.	2.1	1
31	Minimal residual disease detected by multiparameter flow cytometry is complementary to genetics for risk stratification treatment in acute myeloid leukemia with biallelic CEBPA mutations. <i>Leukemia and Lymphoma</i> , 2019, 60, 2181-2189.	1.3	15
32	A novel entity of acute myeloid leukaemia with recurrent RARG-rearrangement resembling acute promyelocytic leukaemia. <i>Leukemia Research</i> , 2019, 77, 14-16.	0.8	15
33	Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients with Intermediate-risk Acute Myelogenous Leukemia in First Complete Remission. <i>Clinical Cancer Research</i> , 2019, 25, 1737-1748.	7.0	26
34	ADAM28 promotes tumor growth and dissemination of acute myeloid leukemia through IGFBP-3 degradation and IGF-I-induced cell proliferation. <i>Cancer Letters</i> , 2019, 442, 193-201.	7.2	12
35	Oral arsenic and all-trans retinoic acid for high-risk acute promyelocytic leukemia. <i>Blood</i> , 2018, 131, 2987-2989.	1.4	36
36	Identification of a novel CPSF6-RARG fusion transcript in acute myeloid leukemia resembling acute promyelocytic leukemia. <i>Leukemia</i> , 2018, 32, 2285-2287.	7.2	32

#	ARTICLE	IF	CITATIONS
37	The initial level of MLL-partial tandem duplication affects the clinical outcomes in patients with acute myeloid leukemia. <i>Leukemia and Lymphoma</i> , 2018, 59, 967-972.	1.3	12
38	The impact of oral arsenic and all-trans-retinoic acid on coagulopathy in acute promyelocytic leukemia. <i>Leukemia Research</i> , 2018, 65, 14-19.	0.8	21
39	Heterogeneous prognosis among KIT mutation types in adult acute myeloid leukemia patients with t(8;21). <i>Blood Cancer Journal</i> , 2018, 8, 76.	6.2	21
40	Oral arsenic plus retinoic acid versus intravenous arsenic plus retinoic acid for non-high-risk acute promyelocytic leukaemia: a non-inferiority, randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2018, 19, 871-879.	10.7	110
41	High EVI1 Expression Predicts Poor Outcomes in Adult Acute Myeloid Leukemia Patients with Intermediate Cytogenetic Risk Receiving Chemotherapy. <i>Medical Science Monitor</i> , 2018, 24, 758-767.	1.1	17
42	Methylation pattern of preferentially expressed antigen of melanoma in acute myeloid leukemia and myelodysplastic syndromes. <i>Oncology Letters</i> , 2017, 13, 2823-2830.	1.8	3
43	The kinetics of white blood cell and the predictive factors of leukocytosis under oral or intravenous arsenic as the first-line treatment for acute promyelocytic leukemia. <i>Leukemia Research</i> , 2017, 61, 84-88.	0.8	8
44	<i>PRAME</i> Gene Copy Number Variation Is Related to Its Expression in Multiple Myeloma. <i>DNA and Cell Biology</i> , 2017, 36, 1099-1107.	1.9	22
45	Arsenic as Traditional Chinese Medicine Provides New Hope for Overcoming High Treatment Costs of Acute Promyelocytic Leukemia. <i>Journal of Global Oncology</i> , 2016, 2, 442-443.	0.5	8
46	B-cell acute lymphoblastic leukemia associated with SET-NUP214 rearrangement: A case report and review of the literature. <i>Oncology Letters</i> , 2016, 11, 2644-2650.	1.8	18
47	Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t(8;21). <i>Leukemia Research</i> , 2016, 44, 40-44.	0.8	29
48	Long-term survival of acute promyelocytic leukaemia patients treated with arsenic and retinoic acid. <i>British Journal of Haematology</i> , 2016, 174, 820-822.	2.5	22
49	Varying responses of PML-RARA with different genetic mutations to arsenic trioxide. <i>Blood</i> , 2016, 127, 243-250.	1.4	26
50	Homoharringtonine combined with aclarubicin and cytarabine synergistically induces apoptosis in t(8;21) leukemia cells and triggers caspase-3-mediated cleavage of the AML1-ETO oncoprotein. <i>Cancer Medicine</i> , 2016, 5, 3205-3213.	2.8	13
51	Low WT1 transcript levels at diagnosis predicted poor outcomes of acute myeloid leukemia patients with t(8;21) who received chemotherapy or allogeneic hematopoietic stem cell transplantation. <i>Chinese Journal of Cancer</i> , 2016, 35, 46.	4.9	11
52	CD38+ CD58 ⁺ is an independent adverse prognostic factor in paediatric Philadelphia chromosome negative B cell acute lymphoblastic leukaemia patients. <i>Leukemia Research</i> , 2016, 43, 33-38.	0.8	16
53	The Initial Level of MLL-PTD Affects the Prognosis of Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2016, 128, 5241-5241.	1.4	0
54	C-KIT- Mutated t(8;21)AML Patients with >3log Reduction of MRD Conferred a Very High Relapse and Need HSCT to Improve Outcome. <i>Blood</i> , 2016, 128, 1620-1620.	1.4	0

#	ARTICLE	IF	CITATIONS
55	The Real World of Arsenic Uses in Chinese with Acute Promyelocytic Leukemia: A Cross-Sectional Survey. <i>Blood</i> , 2016, 128, 5955-5955.	1.4	0
56	Outpatient Oral Treatment for Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 2015, 372, 884-885.	27.0	13
57	Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide. <i>EBioMedicine</i> , 2015, 2, 563-571.	6.1	42
58	Reduced medical costs and hospital days when using oral arsenic plus ATRA as the first-line treatment of acute promyelocytic leukemia. <i>Leukemia Research</i> , 2015, 39, 1319-1324.	0.8	24
59	Allogeneic stem cell transplant may improve the outcome of adult patients with inv(16) acute myeloid leukemia in first complete remission with poor molecular responses to chemotherapy. <i>Leukemia and Lymphoma</i> , 2015, 56, 3116-3123.	1.3	31
60	Varying Responses of PML-Rara with Different Genetic Mutations to Arsenic Trioxide. <i>Blood</i> , 2015, 126, 3678-3678.	1.4	0
61	Oral Arsenic and Retinoic Acid for Non-“High-Risk Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 2014, 371, 2239-2241.	27.0	94
62	Prevalence and prognostic significance of c-KIT mutations in core binding factor acute myeloid leukemia: A comprehensive large-scale study from a single Chinese center. <i>Leukemia Research</i> , 2014, 38, 1435-1440.	0.8	63
63	Resistance to Arsenic Therapy in Acute Promyelocytic Leukemia. <i>New England Journal of Medicine</i> , 2014, 370, 1864-1866.	27.0	113
64	Cytarabine, aclarubicin and granulocyte colony-stimulating factor regimen represents an effective and safe salvage regimen for patients with acute myeloid leukemia refractory to first course of induction chemotherapy. <i>Leukemia and Lymphoma</i> , 2013, 54, 2452-2457.	1.3	15
65	CD34 expression on bone marrow blasts is a novel predictor of poor prognosis independent of FLT3-ITD in acute myeloid leukemia with the NPM1-mutation. <i>Leukemia Research</i> , 2013, 37, 624-630.	0.8	21
66	Oral Tetra-Arsenic Tetra-Sulfide Formula Versus Intravenous Arsenic Trioxide As First-Line Treatment of Acute Promyelocytic Leukemia: A Multicenter Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2013, 31, 4215-4221.	1.6	149
67	MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. <i>Blood</i> , 2013, 121, 4056-4062.	1.4	277
68	Low WT1 Expression At Diagnosis Is a Strong Predictor On Poor Outcome In Patients With t(8;21) Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 1346-1346.	1.4	0
69	Expression of PML-RAR α is up-regulated during ATRA and arsenics combined induction without influence on long-term prognosis of acute promyelocytic leukemia. <i>Zhongguo Shi Yan Xue Ye Xue Za Zhi / Zhongguo Bing Li Sheng Li Xue Hui = Journal of Experimental Hematology / Chinese Association of Pathophysiology</i> , 2013, 21, 872-8.	0.2	1
70	CD34 Expression On the Blasts of Bone Marrow Is a Novel Predictor of Poor Prognosis Independent of FLT3-ITD in Acute Myeloid Leukemia with NPM1-Mutation.. <i>Blood</i> , 2012, 120, 2491-2491.	1.4	0
71	Detecting PML-RAR α transcript in acute promyelocytic leukemia using real-time quantitative RT-PCR. <i>Chinese Medical Journal</i> , 2007, 120, 1803-8.	2.3	2